<DOC>
	<DOCNO>NCT01954745</DOCNO>
	<brief_summary>This research study evaluate drug call cabozantinib possible treatment cancer bile duct . Cabozantinib drug target specific pathway inside cell body . By block c-MET VEGFR2 pathway send signal , cabozantinib may prevent cell multiply . This drug use research study information research study suggest drug may help stop growth bile duct cancer . In research study , investigator look see well cabozantinib work slow growth bile duct cancer . The investigator also assess safety tolerability cabozantinib participant type cancer .</brief_summary>
	<brief_title>Cabozantinib ( XL-184 ) Monotherapy Advanced Cholangiocarcinoma</brief_title>
	<detailed_description>After screen procedure confirm participant eligible participate research study : A two-stage design employ study least 9 20 patient enrol first stage need progression-free 16 week second stage proceed . If criterion meet , additional 24 patient enrolled second stage total 44 patient study . Patients treat cabozantinib 60 mg daily administer orally continuously 28-day cycle . Tumor assessment perform every 8 week document disease progression RECIST criterion drug intolerance . In research study , participant give study drug-dosing diary treatment cycle . Each treatment cycle last 28 day ( 4 week ) , time participant take study drug , cabozantinib daily . The diary also include special instruction take study drug ( ) . The participant continue take cabozantinib long tolerate without unacceptable side effect cancer get bad . The following test procedures do research study : Cycle 1 - On day 1 , 8 15 - Medical History - Physical Exam include vital sign height weight - Performance Status - Review side effect ( day 8 15 ) - Routine blood test ( day 8 15 ) - TSH blood sample day 1 Additional research procedure Cycle 1 : - Biomarker blood sample ( 2 teaspoon blood ) day 3 day 14 Cycles 2-3 - On day 1 15 - Medical History - Physical Exam include vital sign , height weight - Performance Status - Review side effect - EKG - day 1 cycle ONLY - Routine blood test - Urine test Day 1 cycle ONLY - Urine pregnancy test day 1 cycle woman childbearing potential - TSH blood sample day 1 Cycle 4 Beyond : Day 1 ONLY - Medical History - Physical Exam include vital sign , height weight - Performance Status - Review side effect - EKG - Routine blood test - TSH blood sample day 1 - Urine test - Urine pregnancy test woman childbearing potential The following test do every 2 cycle research study : - CA 19-9 blood sample - Tumor measurement - Chest/Abdominal/Pelvic CT/MRI tumor Planned Follow-up : The participant return clinic 30-37 day last dose cabozantinib follow test procedure : - Medical History - Physical Exam include vital sign , height weight - Performance Status - Review side effect - Routine blood test - CA 19-9 blood sample - TSH blood sample</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<criteria>Participants must unresectable metastatic histologically cytologically confirm intrahepatic cholangiocarcinoma extrahepatic cholangiocarcinoma ( i.e . hilar distal cholangiocarcinoma ) . Participants must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) &gt; 20 mm conventional technique &gt; 10 mm spiral CT scan . See section 10 evaluation measureable disease . Participants must fail least 1 2 line systemic regimen advance cholangiocarcinoma due disease progression toxicity . Age ≥ 18 year . Life expectancy ≥ 3 month . ECOG performance status &lt; 1 ( see Appendix A ) . Participants must adequate organ marrow function define : Absolute neutrophil count &gt; 1,500/mcL Platelets &gt; 100,000/mcL Hemoglobin ≥ 9 g/dL Total bilirubin ≤ 2.0 x upper limit normal AST ( SGOT ) /ALT ( SGPT ) ≤ 5 X institutional upper limit normal PT/PTT ≤ 1.5 x ULN Creatinine ≤ 1.5 GFR ≥ 60 mL/min/1.73m2 Lipase &lt; 2.0 x upper limit normal radiologic clinical evidence pancreatitis Serum phosphorus , calcium , magnesium potassium ≥ LLN Urine protein : creatinine ratio ≤ 1 Serum Albumin ≥ 2.8 g/dl Prior chemoembolization , radiofrequency ablation , radiation liver allow long patient measurable disease outside treated area measurable progression site treat area Ability understand willingness sign write informed consent document . Sexually active subject ( men woman ) must agree use medically accept barrier method contraception ( eg , male female condom ) course study 4 month last dose study drug ( ) , even oral contraceptive also use . All subject reproductive potential must agree use barrier method second method birth control course study 4 month last dose study drug ( ) . Women childbearing potential must negative pregnancy test screening . Women childbearing potential include woman experience menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Postmenopause define amenorrhea ≥ 12 consecutive month . Note : woman amenorrheic 12 month still consider childbearing potential amenorrhea possibly due prior chemotherapy , antiestrogens , ovarian suppression reversible reason . Participants exhibit follow condition screen eligible admission study . Prior treatment cabozantinib VEGFR direct therapy Gallbladder carcinoma periampullary tumor Chemotherapy within 4 week prior enter study ( 6 week nitrosoureas mitomycin ) recover adverse event due agent administer 4 week earlier . The subject receive radiation therapy : thoracic cavity , abdomen pelvis within 3 month first dose study treatment ongoing complication without complete recovery heal prior radiation therapy bone brain metastasis within 14 day first dose study treatment site ( ) within 28 day first dose study treatment The subject primary brain tumor . The subject active brain metastasis epidural disease ( Note : Subjects brain metastases previously treat whole brain radiation radiosurgery subject epidural disease previously treat radiation surgery asymptomatic require steroid treatment least 2 week start study treatment eligible . Neurosurgical resection brain metastasis brain biopsy permit complete least 3 month start study treatment . ( Baseline brain imaging contrastenhanced CT MRI scan subject know brain metastasis require confirm eligibility . ) The subject uncontrolled , significant intercurrent recent illness include , limited , following condition : Cardiovascular disorder include Congestive heart failure ( CHF ) : New York Heart Association ( NYHA ) Class III ( moderate ) Class IV ( severe ) time screen Concurrent uncontrolled hypertension define sustain BP &gt; 140 mm Hg systolic , &gt; 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 day first dose study treatment Any history congenital long QT syndrome Any follow within 6 month first dose study treatment : unstable angina pectoris clinicallysignificant cardiac arrhythmia stroke ( include TIA , ischemic event ) myocardial infarction thromboembolic event require therapeutic anticoagulation ( Note : subject venous filter ( e.g . vena cava filter ) eligible study ) Gastrointestinal disorder particularly associate high risk perforation fistula formation include : Any follow within 28 day first dose study treatment intraabdominal tumor/metastases invade GI mucosa active peptic ulcer disease , inflammatory bowel disease ( include ulcerative colitis Crohn 's disease ) , diverticulitis , cholecystitis , symptomatic cholangitis , appendicitis malabsorption syndrome Any follow within 6 month first dose study treatment : abdominal fistula gastrointestinal perforation bowel obstruction gastric outlet obstruction intraabdominal abscess . Note : Complete resolution intraabdominal abscess must confirm prior initiating treatment cabozantinib even abscess occur 6 month first dose study treatment . Other disorder associate high risk fistula formation include PEG tube placement within 3 month first dose study therapy Other clinically significant disorder : active infection require systemic treatment within 28 day first dose study treatment serious nonhealing wound/ulcer/bone fracture within 28 day first dose study treatment history organ transplant concurrent uncompensated hypothyroidism thyroid dysfunction within 7 day first dose study treatment history major surgery follow : Major surgery within 3 month first dose cabozantinib wound heal complication within 6 month first dose cabozantinib wound complication Minor surgery within 1 month first dose cabozantinib wound heal complication within 3 month first dose cabozantinib wound complication Clinically significant gastrointestinal bleeding within six month first dose study treatment Previous history pulmonary embolism deep venous thrombosis Severely impaired lung function history interstitial lung disease Concurrent malignancy ( adequately treat nonmelanoma skin cancer , superficial transitional cell carcinoma bladder , cervical carcinoma situ ) diagnose within past 3 year currently active malignancy Psychiatric illness/social situation would limit compliance study requirement . The subject history clinically significant hematemesis , hemoptysis &gt; 2.5 mL red blood , radiation ( include brachytherapy ) pulmonary lesion , sign indicative significant pulmonary hemorrhage within 3 month first dose study treatment . The subject radiographic evidence cavitating pulmonary lesion ( ) The subject lesion abutting , invading , encase major blood vessel . The subject evidence tumor invade GI tract ( esophagus , stomach , small large bowel , rectum anus ) , evidence endotracheal endobronchial tumor within 28 day first dose cabozantinib . The subject receive type investigational agent within 28 day first dose study treatment . The subject correct QT interval calculate Fridericia formula ( QTcF ) &gt; 500 m within 28 day randomization . . Note : initial QTcF find &gt; 500 m , two additional EKGs separate least 3 minute perform . If average three consecutive result QTcF ≤ 500 m , subject meet eligibility regard History allergic reaction attribute compound similar chemical biologic composition cabozantinib . The subject require concomitant treatment , therapeutic dos , anticoagulant warfarin , warafarinrelated agent , heparin , thrombin inhibitor , Factor Xa inhibitor , antiplatelet agent ( eg , clopidogrel ) . Low dose aspirin ( ≤ 81 mg/day ) , lowdose warfarin ( ≤ 1 mg/day ) , prophylactic Low Molecular Weight Heparin ( LMWH ) permit . The subject require concomitant use strong CYP3A4 inducer ( eg , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. John 's Wort ) strong CYP3A4 inhibitor ( eg , ketoconazole , itraconazole , clarithromycin , indinavir , nefazodone , nelfinavir , ritonavir ) . The subject receive prior treatment small molecule kinase inhibitor hormonal therapy ( include investigational kinase inhibitor hormone ) within 14 day five halflives compound active metabolite , whichever longer , first dose study treatment . Note : Subjects prostate cancer currently receive LHRH GnRH agonist may maintain agent . The subject unable swallow tablet Individuals know HIVpositive exclude study . HIV positive individual increase risk lethal infection treat marrowsuppressive agent , cabozantinib adequately test population . Also , antiretroviral therapy may pharmacokinetic interaction cabozantinib fully characterize yet . Pregnant woman exclude study due potential teratogenic abortifacient effect . Because unknown potential risk adverse event nurse infant secondary treatment mother cabozatinib , breastfeed discontinue mother treated cabozantnib . These potential risk may also apply agent use study . Subjects may receive study agent concurrently study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Bile Duct Cancer</keyword>
	<keyword>intrahepatic cholangiocarcinoma</keyword>
	<keyword>extrahepatic cholangiocarcinoma</keyword>
	<keyword>Cabozantinib</keyword>
</DOC>